Medytox

Medytox is a South Korean biopharmaceutical company with a prominent botulinum toxin type A portfolio. Its product lines connect Korean toxin manufacturing, formulation differences, export naming, regional approval records, and the competitive expansion of newer type A brands.

The company is associated with several type A toxin names, including Meditoxin / Neuronox, INNOTOX, Coretox, and NEWLUX. Those names do not represent one uniform global product. They sit across different presentations, labels, markets, and regulatory histories.

Reference card

| Field | Reference point | | --- | --- | | Company | Medytox Inc. | | Base | South Korea | | Website | medytox.com | | Listing status | KOSDAQ-listed since 2009; ticker code 086900:KOSDAQ | | Manufacturing footprint | Medytox lists three Korean manufacturing plants, a Gwanggyo R&D Center, and a Seoul Global Business Center across Ochang, Osong, Gwanggyo, and Gangnam. | | Core toxin relationship | Developer and manufacturer of botulinum toxin type A products | | Main toxin names | Meditoxin / Neuronox, INNOTOX, Coretox, NEWLUX | | Comparison anchors | Botox, Dysport, Xeomin, and Jeuveau | | Unit context | Shared type A biology does not make brands unit-equivalent, interchangeable, or equally approved across countries. |

Selected history

2006: Meditoxin approval Medytox company materials describe Meditoxin 100U as Korea’s first approved botulinum toxin type A product and the fourth such product globally.
2009: KOSDAQ listing Medytox listed on KOSDAQ, making it easier to track the company as a public-market participant rather than only as a product manufacturer.
2013-2016: INNOTOX and Coretox Medytox materials describe MFDS approval for INNOTOX as a non-animal-derived liquid formulation in 2013 and Coretox 100U approval in 2016.
2021-2024: litigation settlements and NEWLUX The company reached settlements tied to U.S. intellectual-property litigation in 2021 and launched NEWLUX in Korea in 2023, while continuing distribution and manufacturing-expansion activity through 2024.

Product portfolio

Medytox’s botulinum toxin business includes several type A product lines, led by Meditoxin / Neuronox and followed by INNOTOX, Coretox, and NEWLUX. The names mark more than brand extension: they point to different presentations, product-information records, and approval contexts across markets.

| Product name | First approval or launch context | Presentation | Protein / formulation context | | --- | --- | --- | --- | | Meditoxin / Neuronox | KFDA approval for Meditoxin 100U in 2006; first overseas registration as Neuronox in Bolivia in 2013. | Lyophilized powder for injection. | Type A product using the Hall strain; unit language remains product-specific. | | INNOTOX | MFDS approval for INNOTOX 25U in 2013, with later unit approvals listed in company history. | Liquid-filled injection. | Medytox describes INNOTOX as a non-animal-derived liquid formulation. | | Coretox | MFDS approval for Coretox 100U in 2016. | Lyophilized powder for injection. | Korean product information lists botulinum toxin type A 150kD as the active toxin component. | | NEWLUX | NUMECO launched NEWLUX in 2023 after MFDS application activity in 2022. | Lyophilized powder for injection. | Korean product information lists human serum albumin and sodium chloride as excipients. |

The shared thread across these products is type A toxin biology, while practical details remain product-specific. Cross-brand comparison with Botox, Dysport, Xeomin, Jeuveau, Letybo, Daxxify, or other products depends on product-specific labeling, evidence context, and regional availability rather than broad market language alone.

Meditoxin / Neuronox

Meditoxin is Medytox’s original botulinum toxin type A product line and the product most closely tied to the company’s early manufacturing identity. Medytox history materials describe KFDA approval for Meditoxin 100U in 2006 and later overseas registration under the Neuronox name.

The Medytox English product page describes Meditoxin / Neuronox as a lyophilized white powder for injection with clostridium botulinum toxin type A as the active ingredient. That presentation separates it from INNOTOX’s liquid format, but it does not make the product comparable by unit count to Botox, Dysport, Xeomin, Jeuveau, Letybo, Daxxify, or other type A brands.

Associated export names:

Botulift
Acebloc
Cunox
Siax

These names reflect market-facing product identities listed by Medytox, while local labeling and approval status remain market-specific.

INNOTOX

INNOTOX is Medytox’s liquid botulinum toxin type A product line. Medytox history materials describe MFDS approval for INNOTOX 25U in 2013 as a non-animal-derived liquid formulation, followed by later unit approvals.

The liquid presentation is the main practical distinction at the portfolio level: it is supplied as a colorless transparent liquid-filled injection rather than a lyophilized powder that is reconstituted before use. Storage, expiry, indication language, and dose interpretation still belong to the specific product label, not to the broad fact that it is a type A toxin.

INNOTOX should not be treated as a general liquid equivalent of other botulinum toxin products. The format changes handling context, while potency units, approved uses, and clinical decisions remain product- and region-specific.

Coretox

Coretox is a separate Medytox botulinum toxin type A product line approved after Meditoxin and INNOTOX. Medytox history materials list MFDS approval for Coretox 100U in 2016.

Korean product information lists the active toxin component as clostridium botulinum toxin type A 150kD. That makes Coretox important in Medytox’s portfolio because it is framed around the neurotoxin component rather than the larger complexing-protein presentation associated with many older type A products.

The protein-composition point should be interpreted narrowly. It may matter for formulation comparison and immunogenicity discussion, but it does not by itself establish superior clinical effect, longer duration, lower adverse-event risk, or unit equivalence with other type A products.

Coretox is described by Medytox as a lyophilized powder for injection. As with other toxin products, approved indications and practical use depend on the product label and the market where it is supplied.

NEWLUX

NEWLUX is the newest botulinum toxin type A name in the Medytox portfolio. Company history materials describe a 2022 MFDS application for NEWLUX and a 2023 launch by NUMECO, the renamed Medytox Korea subsidiary.

The Korean product page describes NEWLUX 100U as a lyophilized white powder in a vial that becomes a clear solution after dilution with saline. It also lists human serum albumin and sodium chloride among the product’s excipients.

Associated export name: Metatox.

NEWLUX is useful to distinguish from Meditoxin / Neuronox because it reflects a newer product cycle and a separate approval context, not because it can be ranked against other Medytox products on broad claims such as strength, safety, or duration. Its interpretation should stay tied to official product information and local regulatory records.

Manufacturing and research sites

Medytox’s Korean infrastructure connects product manufacturing, formulation development, research, domestic commercialization, and global business coordination. This site network is useful for interpreting Medytox as a manufacturer with multiple product lines, not only as the owner of several toxin brand names.

Plant I: Ochang

Medytox describes Plant I in Ochang as Korea’s first botulinum toxin type A manufacturing facility and as a dedicated site for botulinum toxin and finished-product manufacturing. The company states that Plant I obtained MFDS GMP approval for biologics and injectables.

Location: 78, Gangni-1gil, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.

Plant II: Osong

Plant II in Osong is presented by Medytox as a site for liquid-type botulinum toxin type A production, including MT10109L-related manufacturing context. The company describes the facility as designed to meet U.S. FDA cGMP standards and European EMA GMP standards. That wording is facility-design context rather than a statement that the site has FDA or EMA approval.

Location: 71, Osongsaengmyeong 6-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.

Plant III: Osong

Plant III in Osong is described as a facility for botulinum toxin type A and hyaluronic acid filler products. Medytox describes the site as cGMP / EU GMP compliant in company materials, while the explicit approvals it lists here are Korean KGMP approvals for botulinum toxin production in 2016 and filler production in 2018. In November 2024, Medytox also obtained KGMP approval for the Plant III E-wing, a newer large-scale production line.

Location: 102, Osongsaengmyeong 4-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea.

R&D center: Gwanggyo

Medytox lists a Gwanggyo R&D Center in Suwon, described as a multi-level biolab intended to support drug-development research from discovery work toward clinical-stage preparation.

Gwanggyo R&D Center: 114, Central-Town-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea.

Global Business Center: Seoul

The Medytox Global Business Center in Gangnam, Seoul, is the company’s business-coordination site. Medytox describes it as managing domestic business units and Korean plants while also coordinating overseas entities in markets including Japan, Thailand, Taiwan, and Hong Kong.

Location: Medytox Building, 626, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea.

Market role

Medytox reflects the shift from a botulinum toxin market dominated by older Western brands toward a more distributed competitive field. Korean manufacturers now shape aesthetic-market competition, export strategy, manufacturing disputes, and the expansion of type A product choices across regions.

Its portfolio also separates several layers that are often compressed in public discussion: company, product, formulation, export name, and local approval status. A single manufacturer can hold multiple toxin product lines without making them clinically interchangeable or uniformly approved across markets.

Regulatory and market interpretation

Medytox product visibility is regional rather than universal. A product listed on a company website, or used in one country, may have a different approval status, indication set, distribution channel, or prescribing framework elsewhere. In the United States, FDA-approved cosmetic botulinum toxin products are defined by FDA records rather than by online availability or foreign-market product names.

Medytox is also part of a well-known intellectual-property and trade-secret dispute history involving Daewoong, Evolus, and AbbVie / Allergan. The U.S. International Trade Commission found a Section 337 violation in 2020 based on Medytox manufacturing trade secrets, not the Medytox bacterial strain; later settlement activity allowed Evolus to continue commercializing Jeuveau in its licensed territories. That history shaped market structure and company relationships, not clinical superiority claims among botulinum toxin products.

Comparison limits

Online product visibility does not establish approval in a given country.
Meditoxin, Neuronox, INNOTOX, Coretox, and NEWLUX are not unit-for-unit substitutes for other type A products.
Legal or commercial settlements do not establish clinical equivalence, safety advantage, or duration advantage.
Indication language from one country does not automatically transfer to another country’s clinical setting.